|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Immunohistochemical analysis of the Wnt/β-catenin signaling pathway in pancreatic neuroendocrine neoplasms显示文摘AIM: To investigate the role of the Wnt/β-catenin pathway in pancreatic neuroendocrine neoplasms(PanN ENs). METHODS: Tissue microarrays containing 88 PanN ENs were immunohistochemically labeled with antibodies to β-catenin, E-cadherin, adenomatous polyposis coli(APC), chromogranin and synaptophysin. One case had only metastatic tumors resected, whereas others(n = 87) received pancreatectomy with or without partial hepatectomy. Pathology slides, demographic, clinicopathologic, and follow up data were reviewed. Patients' demographics, clinicopathologic features, and immunohistochemical results from 87 primary tumors were compared between patients with low stage(stage Ⅰ/Ⅱ) and high stage(stage Ⅲ/Ⅳ) tumors. In addition, correlation of immunohistochemical results from primary tumors with disease-specific survival(DSS) was evaluated. RESULTS: Strong membranous β-catenin staining in the primary tumor was observed in all 13 stage Ⅲ/Ⅳ Pan NENs as compared to 47%(35/74) of stage Ⅰ/Ⅱtumors(P < 0.01). However, the strong membranous β-catenin staining was unassociated with tumor grade or DSS. Decreased membranous β-catenin staining was associated with decreased membranous E-cadherin labeling. Nuclear β-catenin staining was seen in 15%(2/13) of stage Ⅲ/Ⅳ Pan NENs as compared to 0%(0/74) of stage Ⅰ/Ⅱ tumors(P = 0.02). The case with metastasectomy only also showed nuclear β-catenin staining. Two of the three cases with nuclear β-catenin staining were familial adenomatous polyposis(FAP) patients. Lack of APC expression was seen in 70%(57/81) of the cases, including the 3 cases with nuclear β-catenin staining. Expression of E-cadherin and APC in primary tumor was not correlated with tumor grade, tumor stage, or disease specific survival. CONCLUSION: The Wnt/β-catenin pathway was altered in some PanN ENs, but did not Impact DSS. PanN ENs in FAP patients demonstrated nuclear β-catenin accumulation and loss of APC. | Vivian Weiss Julie Dueber Jesse P Wright Justin Cates Frank Revetta Alexander A Parikh Nipun B Merchant Chanjuan Shi | 2016 | World Journal of Gastrointestinal Oncology2016，8，8： | 3 |
| 2 | Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: Results from a randomized, placebocontrolled, multicentre study (Iressa Survival Evaluation in Lung Cancer)显示文摘 | Thatcher N Chang A Parikh P | 2005 | Lancet2005，366，9496： | 1 |
| 3 | Solvent free aldol condensation of propanal to 2-methylpentenal using solid base catalysts 显示文摘 | SHARMA S K PARIKH P A JASRA R V | 2007 | Journal of Molecular Catalysis A: Chemical2007，278，12： | 1 |
| 4 | An overview of GaN Growth Chemistry and Its Effect on Reactor Design : Application to a Planetary Radial-flow CVD System显示文摘 | Parikh R P Adomaitis R A | 2006 | Journal of Crystal Growth2006，286，： | 1 |
| 5 | Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised placebo-controlled, multicentre study (Iressa Survival Evalua tion in Lung Cancer)显示文摘 | Thatcher N Chang A Parikh P | 2005 | Lancet2005，366，： | 1 |
| 6 | Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer:results from a randomized,placebo-controlled,multicentre study (Iressa Survival Evaluation in Lung Cancer)显示文摘 | Thatcher N Chang A Parikh P | | 0，，9496： | 1 |
| 7 | Gefitinib plus best supportive are in previously treated patients with refractory advanced non-small cell lung carcinoma: results from a randomized, placebo-controlled, multicenter study 显示文摘 | Thatcher N Chang A Parikh P | 2005 | Lancet2005，366，： | 1 |
| 8 | Gefitinib plus best supportive care in previously treated patients with refractory advanced non small cell lung cancer results from a randomized placebo controlled multicentre study (Iressa Survival Evaluation In Lung Cancer)显示文摘 | Thatcher N Chang A Parikh P | 2005 | Lancet2005，366，： | 1 |
| 9 | The Mycobacterium tuberculosis protein kinase K modulates activation of transcription from the promoter of mycobacterial monooxygenase operon through phosphorylation of the transcriptional regulator VirS显示文摘 | Kumar P Kumar D Parikh A Rananaware D Gupta M Singh Y Nandicoori VK | 2009 | J Biol Chem2009，284，11： | 1 |
| 10 | A unified corre- lation for estimating HHV of solid, liquid and gaseous fuels显示文摘 | CHANNIWALA S A PARIKH P P | 2002 | Fuel2002，81，8： | 1 |
| 11 | Gefitinib plus kest supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomized, placebocontrolled, multicentre study (Iressa Survival Evaluation in lung cancer)显示文摘 | Thatcher N Chang A Parikh P | 2005 | Lancet2005，366，9496： | 1 |
| 12 | Gefitinib plus best supportive carein previously treated patients with refractory advanced non-small-cell lung cancer: results from a random- ised, placebo-controlled, multicentrestudy (Iressa Survival E- valuation in Lung Cancer) 显示文摘 | Thatcher N Chang A Parikh P | 2005 | Lancet2005，366，9496： | 1 |
| 13 | Gefitinib plus best supportive care in previously treated patients with refractory advanced non - small cell lung cancer: results from a randomized, placebo - controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer) 显示文摘 | Thatcher N Chang A Parikh P | 2005 | Lancet2005，366，： | 1 |
| 14 | Gefitinib plus best supportive care in previously treated patients with refaetory advanced non small-cell lung cancer: Results from a random- ised, placebo-controlled, multicentre study (IRESSA survival evaluation in lung cancer)显示文摘 | Thatcher N Chang A Parikh P | 2005 | Lancet2005，366，9496： | 1 |
| 15 | Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebocontrolled, multicentre study Cancer) 显示文摘 | Thatcher N Chang A Parikh P | 2005 | LANCET2005，，9496： | 1 |
| 16 | Gefitinib plus best supportive care in previously treated patients with refractory advanced non-smallcell lung cancer:results from a randomised,placebo-controlled,multicentre study (Iressa Survival Evaluation in Lung Cancer)显示文摘 | Thatcher N Chang A Parikh P | | 0，，9496： | 1 |
| 17 | Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small- cell lung cancer: results from a randomised, placebo-controlled, mul- ticentre study (Iressa Survival Evaluation in Lung Cancer) 显示文摘 | Thatcher N Chang A Parikh P | 2005 | Lan- cet2005，366，9496： | 1 |
| 18 | Gefitinib plus best in previously treated patients with refractory advanced non-small cell lung cancer:results from a randomized, placebo-controlled,multicentre study(Iressa Survival Evaluation in Lung Cancer)显示文摘 | Thatcher N Chang A Parikh P | 2005 | Lancet2005，366，9496： | 1 |
| 19 | Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small cell lung cancer: subset analysis from the ISEL study 显示文摘 | Chang A Parikh P Thongprasert S | 2006 | J Thorac Oncol2006，1，8： | 1 |
| 20 | Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a random- ised, placebo controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)显示文摘 | Thatcher N Chang A Parikh P | 2005 | Lancet2005，366，9496： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员